GLAND PHARMA LIMITED

Key Quantitative Figures

  • Total shares allotted: 44,193 equity shares of Re. 1 each
  • ESOP 2019 allotment: 1,800 shares to 1 employee
  • ESOP 2025 allotment: 42,393 shares to 35 employees
  • Exercise prices:
  • ESOP 2019: ₹542 per share (1,800 options)
  • ESOP 2025: ₹773.30 per share (24,529 options), ₹937.20 per share (3,444 options), ₹1 per share (14,420 options)
  • Premium per share:
  • ESOP 2019: ₹541 per share
  • ESOP 2025: ₹772.30 per share (24,529 options), ₹936.20 per share (3,444 options), Nil (14,420 options)
  • Post-allotment share capital: ₹165,010,854
  • Post-allotment total shares: 165,010,854 equity shares
  • Distinctive numbers: 164,966,662 to 165,010,854 (both inclusive)

Dates of Action

  • Committee meeting date: September 13, 2026
  • Date of allotment: September 13, 2026
  • ESOP 2025 filing date: May 03, 2025 (BSE & NSE)

Parties Involved

  • ESOP Compensation Committee of the Board of Directors approved the allotment
  • 36 employees received shares (35 under ESOP 2025, 1 under ESOP 2019)
  • Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, signed the disclosure

Capital Structure Impact

  • Issued, subscribed and paid-up share capital increased from previous undisclosed amount to ₹165,010,854
  • Total number of equity shares increased to 165,010,854
  • New shares rank pari passu with existing shares
  • No lock-in restrictions on the allotted shares

Scheme Details

  • ESOP 2019: Formally closed and wound up with immediate effect as all eligible options have been fully exercised/lapsed
  • ESOP 2025: Active scheme with ongoing allocations
  • Shares issued in dematerialized form (no physical share certificates)

Financial Impact

  • Total premium received: Approximately ₹3.98 crore calculated as follows:
  • ESOP 2019: 1,800 shares × ₹541 premium = ₹973,800
  • ESOP 2025: (24,529 × ₹772.30) + (3,444 × ₹936.20) + (14,420 × ₹0) = ₹18,943,297 + ₹3,224,273 + ₹0 = ₹22,167,570
  • Total: ₹973,800 + ₹22,167,570 = ₹23,141,370
  • Cash inflow from exercise prices: Approximately ₹2.65 crore